Key Points
- Summarize the distinct contributions of various adipose tissue depots to metabolic syndrome and evaluate how mitochondrial-targeted agents modulate fat depot size.
- Synthesized literature on depot-specific gene expression profiles, lipolysis rates, and adipokine secretion across adipose tissues.
- Examined mechanistic evidence evaluating the effects of the modified fatty acid tetradecylthioacetic acid (TTA) on mitochondrial activity and adipose mass.
- Depot-specific differences in gene expression and cytokine release drive variation in systemic lipolysis, insulin resistance, and cardiovascular risk.
- Mitochondrial-targeted intervention with tetradecylthioacetic acid (TTA) alters mitochondrial function and selectively decreases the size of specific fat depots.
Structured PICO
IInterventionTetradecylthioacetic acid (TTA)
This review highlights the differential metabolic impacts of various adipose depots and the potential of tetradecylthioacetic acid (TTA) to modulate mitochondrial function and reduce specific fat depots.